Table 1.
Open in new tab

Characteristics of Patients in the United Kingdom Collaborative HIV Cohort Study Who Were Exposed to Tenofovir Disoproxil Fumarate (TDF) for ≥6 Months

CharacteristicValue
Male sex10 550(81.1)
Ethnicity
 White8300(63.8)
 Black3026(23.3)
 Other/unknown1681(12.9)
Route of HIV exposure
 Homosexual/bisexual sex8236(63.3)
 Heterosexual sex3713(28.6)
 IDU356(2.7)
 Other/unknown702(5.4)
Calendar year
 1999–20032482(19.1)
 2004–20073992(30.7)
 2008–20106533(50.2)
Previous exposure to TDF603(4.6)
ART naive4466(34.4)
ARV class
 PI based (no ATZ)2690(20.7)
 PI based (with ATZ)1329(10.2)
 NNRTI based7098(54.6)
 Other1890(14.5)
Previous AIDS-defining event3053(23.5)
HBV status
 Negative8412(64.7)
 Positive599(4.6)
 Not tested3996(30.7)
HCV status
 Negative8619(66.3)
 Positive730(5.6)
 Not tested3658(28.1)
eGFR
 <60 mL/min/1.73 m2166(1.4)
 60–74 mL/min/1.73 m2985(8.5)
 75–89 mL/min/1.73 m22572(22.1)
 ≥90 mL/min/1.73 m27898(68.0)
Age, y40(34–46)
CD4+ T-cell count, cells/mm3303(190–482)
HIV load, log10 copies/mL2.9(1.7–4.7)
CharacteristicValue
Male sex10 550(81.1)
Ethnicity
 White8300(63.8)
 Black3026(23.3)
 Other/unknown1681(12.9)
Route of HIV exposure
 Homosexual/bisexual sex8236(63.3)
 Heterosexual sex3713(28.6)
 IDU356(2.7)
 Other/unknown702(5.4)
Calendar year
 1999–20032482(19.1)
 2004–20073992(30.7)
 2008–20106533(50.2)
Previous exposure to TDF603(4.6)
ART naive4466(34.4)
ARV class
 PI based (no ATZ)2690(20.7)
 PI based (with ATZ)1329(10.2)
 NNRTI based7098(54.6)
 Other1890(14.5)
Previous AIDS-defining event3053(23.5)
HBV status
 Negative8412(64.7)
 Positive599(4.6)
 Not tested3996(30.7)
HCV status
 Negative8619(66.3)
 Positive730(5.6)
 Not tested3658(28.1)
eGFR
 <60 mL/min/1.73 m2166(1.4)
 60–74 mL/min/1.73 m2985(8.5)
 75–89 mL/min/1.73 m22572(22.1)
 ≥90 mL/min/1.73 m27898(68.0)
Age, y40(34–46)
CD4+ T-cell count, cells/mm3303(190–482)
HIV load, log10 copies/mL2.9(1.7–4.7)

Data are no. (%) of patients or median value (interquartile range) and were recorded at the start of TDF therapy.

Abbreviations: ART, antiretroviral therapy; ARV, antiretroviral; ATZ, atazanavir; eGFR, estimate glomerular filtration rate; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodeficiency virus; IDU, injection drug use; PI, protease inhibitor; NNRTI, nonnucleoside reverse-transcriptase inhibitor; NRTI, nucleoside reverse-transcriptase inhibitor.

a

Data are for 11 621 patients with eGFR measure available in the 6 months preceding TDF therapy.

Table 1.
Open in new tab

Characteristics of Patients in the United Kingdom Collaborative HIV Cohort Study Who Were Exposed to Tenofovir Disoproxil Fumarate (TDF) for ≥6 Months

CharacteristicValue
Male sex10 550(81.1)
Ethnicity
 White8300(63.8)
 Black3026(23.3)
 Other/unknown1681(12.9)
Route of HIV exposure
 Homosexual/bisexual sex8236(63.3)
 Heterosexual sex3713(28.6)
 IDU356(2.7)
 Other/unknown702(5.4)
Calendar year
 1999–20032482(19.1)
 2004–20073992(30.7)
 2008–20106533(50.2)
Previous exposure to TDF603(4.6)
ART naive4466(34.4)
ARV class
 PI based (no ATZ)2690(20.7)
 PI based (with ATZ)1329(10.2)
 NNRTI based7098(54.6)
 Other1890(14.5)
Previous AIDS-defining event3053(23.5)
HBV status
 Negative8412(64.7)
 Positive599(4.6)
 Not tested3996(30.7)
HCV status
 Negative8619(66.3)
 Positive730(5.6)
 Not tested3658(28.1)
eGFR
 <60 mL/min/1.73 m2166(1.4)
 60–74 mL/min/1.73 m2985(8.5)
 75–89 mL/min/1.73 m22572(22.1)
 ≥90 mL/min/1.73 m27898(68.0)
Age, y40(34–46)
CD4+ T-cell count, cells/mm3303(190–482)
HIV load, log10 copies/mL2.9(1.7–4.7)
CharacteristicValue
Male sex10 550(81.1)
Ethnicity
 White8300(63.8)
 Black3026(23.3)
 Other/unknown1681(12.9)
Route of HIV exposure
 Homosexual/bisexual sex8236(63.3)
 Heterosexual sex3713(28.6)
 IDU356(2.7)
 Other/unknown702(5.4)
Calendar year
 1999–20032482(19.1)
 2004–20073992(30.7)
 2008–20106533(50.2)
Previous exposure to TDF603(4.6)
ART naive4466(34.4)
ARV class
 PI based (no ATZ)2690(20.7)
 PI based (with ATZ)1329(10.2)
 NNRTI based7098(54.6)
 Other1890(14.5)
Previous AIDS-defining event3053(23.5)
HBV status
 Negative8412(64.7)
 Positive599(4.6)
 Not tested3996(30.7)
HCV status
 Negative8619(66.3)
 Positive730(5.6)
 Not tested3658(28.1)
eGFR
 <60 mL/min/1.73 m2166(1.4)
 60–74 mL/min/1.73 m2985(8.5)
 75–89 mL/min/1.73 m22572(22.1)
 ≥90 mL/min/1.73 m27898(68.0)
Age, y40(34–46)
CD4+ T-cell count, cells/mm3303(190–482)
HIV load, log10 copies/mL2.9(1.7–4.7)

Data are no. (%) of patients or median value (interquartile range) and were recorded at the start of TDF therapy.

Abbreviations: ART, antiretroviral therapy; ARV, antiretroviral; ATZ, atazanavir; eGFR, estimate glomerular filtration rate; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodeficiency virus; IDU, injection drug use; PI, protease inhibitor; NNRTI, nonnucleoside reverse-transcriptase inhibitor; NRTI, nucleoside reverse-transcriptase inhibitor.

a

Data are for 11 621 patients with eGFR measure available in the 6 months preceding TDF therapy.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close